Targeting the cellular prion protein to treat neurodegeneration

Future Medicinal Chemistry

Volumn 4, Issue 13, 2012, Pages 1655-1658

  Biasini, Emiliano ^a   Harris, David A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimers disease; drugs; neurodegeneration; prion; therapy

Indexed keywords

AMPHOTERICIN B; CONGO RED; MEPACRINE; PENTOSAN POLYSULFATE; PRION PROTEIN; PROTEIN INHIBITOR; TETRACYCLINE;

ALZHEIMER DISEASE; DRUG RESEARCH; DRUG TARGETING; HUMAN; NERVE DEGENERATION; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

ANIMALS; CREUTZFELDT-JAKOB SYNDROME; GERSTMANN-STRAUSSLER-SCHEINKER DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; PRPC PROTEINS;

EID: 84865749808     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.114     Document Type: Review

References (20)

1. Prusiner SB. Prions. Proc. Natl Acad. Sci. USA 95, 13363-13383 (1998).
2. Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 129(Pt 9), 2241-2265 (2006).
3. Sim VL. Prion disease: chemotherapeutic strategies. Infect. Disord. Drug Targets 12(2), 144-160 (2012).
4. Collinge J, Gorham M, Hudson F et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol. 8(4), 334-344 (2009).
5. Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470(7335), 540-542 (2011).
6. Harris DA, True HL. New insights into prion structure and toxicity. Neuron 50(3), 353-357 (2006).
7. Brandner S, Isenmann S, Raeber A et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379, 339-343 (1996).
8. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302(5646), 871-874 (2003).
9. White MD, Farmer M, Mirabile I, Brandner S, Collinge J, Mallucci GR. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc. Natl Acad. Sci. USA 105(29), 10238-10243 (2008).
10. Biasini E, Turnbaugh JA, Unterberger U, Harris DA. Prion protein at the crossroads of physiology and disease. Trends Neurosci. 35(2), 92-103 (2012).
11. Poncet-Montange G, St Martin SJ, Bogatova OV, Prusiner SB, Shoichet BK, Ghaemmaghami S. A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets. J. Biol. Chem. 286(31), 27718-27728 (2011).
12. Kuwata K, Nishida N, Matsumoto T et al. Hot spots in prion protein for pathogenic conversion. Proc. Natl Acad. Sci. USA 104(29), 11921-11926 (2007).
13. Nicoll AJ, Trevitt CR, Tattum MH et al. Pharmacological chaperone for the structured domain of human prion protein. Proc. Natl Acad. Sci. USA 107(41), 17610-17615 (2010).
14. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol. Brain 4, 3 (2011).
15. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J. Neurochem. 101(5), 1172-1184 (2007).
16. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457(7233), 1128-1132 (2009).
17. Gimbel DA, Nygaard HB, Coffey EE et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J. Neurosci. 30(18), 6367-6374 (2010).
18. Freir DB, Nicoll AJ, Klyubin I et al. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat. Commun. 2, 336 (2011).
19. Balducci C, Beeg M, Stravalaci M et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc. Natl Acad. Sci. USA 107(5), 2295-2300 (2010).
20. Resenberger UK, Harmeier A, Woerner AC et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J. 30(10), 2057-2070 (2011).